Garcia-Romeu A

Development of Japanese Versions of the 4-Item Mystical Experience Questionnaire and 7-Item Challenging Experience Questionnaire.

Umemura F, Kotajima-Murakami H, Strickland JC +3

Setting, context and the regulatory atmospheres of psychedelic medicine.

Gearin AK, Cohen IG, Garcia-Romeu A

Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations

Nayak SM, Sepeda ND, Dick MN +8

Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.

Baral A, Pan Y, Hlaing WM +3

Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial.

Johnson MW, Naudé GP, Hendricks PS +1

Pilot study of psilocybin in patients with post-treatment lyme disease.

Garcia-Romeu A, Naudé GP, Rebman AW +7

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones.

Goldy SP, Sepeda ND, Hilbert SN +6

Psychedelics for the management of symptoms of traumatic brain injury: Findings from the global psychedelic survey.

VanderZwaag B, Robinson J, Garcia-Romeu A +3

Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics.

Henningfield JE, Barrett FS, Evans SM +9

Exploring self-reported health behavior change following naturalistic psychedelic use.

Carvalho LC, Encantado J, Moller AC +6

Association between lifetime co-use of classic psychedelics and cannabis and prostate cancer diagnosis among US adults 50 years and older.

Baral A, Pan Y, Hlaing WM +3

Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics?

Garcia-Romeu A

Self-Reported Improvements in Comorbid Post-Traumatic Stress Disorder Symptoms, Depression, Anxiety, and Sleep Among Real-World Patients Receiving Medical Ketamine: Exploring the Role of Adjunct Therapies.

Almog S, Garcia-Romeu A, Walker KA +2

Attitudes and Perceptions of Portuguese Psychiatrists and Psychologists on the Clinical Use of Ketamine.

Mota P, Encantado J, C Carvalho L +4

Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories.

Healy CJ, Frazier A, Kirsch S +5

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Yaden DB, Graziosi M, Owen AM +39

Expanded access to psychedelic treatments: comparing American and Canadian policies.

Richard J, Garcia-Romeu A, Henningfield JE

Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use.

Mathai DS, Roberts DE, Nayak SM +6

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.

Wang E, Mathai DS, Gukasyan N +2

Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study.

Jones G, Lowe MX, Nayak S +5

Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Psychedelic Medicine

Garcia-Romeu A

Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery.

VanderZwaag B, Garcia-Romeu A, Garcia-Barrera MA

ArticleMDMA

Ethnoracial inclusion in clinical trials of psychedelics: a systematic review.

Hughes ME, Garcia-Romeu A

Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study.

Nayak SM, White SH, Hilbert SN +5

The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item.

Strickland JC, Garcia-Romeu A, Johnson MW

Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer.

Thrul J, Kozak Z, Carducci MA +2

Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers.

Mathai DS, Hilbert S, Sepeda ND +3

IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.

Yaden DB, Berghella AP, Hendricks PS +6

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use

Mathai DS, Roberts DE, Nayak SM +6

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use

Mathai DS, Roberts DE, Nayak SM +6

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey.

Nayak SM, Jackson H, Sepeda ND +13

Psilocybin's effects on cognition and creativity: A scoping review.

Bonnieux JN, VanderZwaag B, Premji Z +2

Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study

Nayak SM, White S, Hilbert S +5

Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study

Nayak SM, White SH, Hilbert S +5

Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine.

Mathai DS, Nayak SM, Yaden DB +1

Toward Synergies of Ketamine and Psychotherapy.

Mathai DS, Mora V, Garcia-Romeu A

Psychedelic Identity Shift: A Critical Approach to Set And Setting.

Devenot N, Seale-Feldman A, Smith E +3

Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.

Garcia-Romeu A, Darcy S, Jackson H +2

Ancient Roots of Today's Emerging Renaissance in Psychedelic Medicine.

George DR, Hanson R, Wilkinson D +1

Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.

Yaden DB, Johnson MW, Griffiths RR +6

Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives.

Cox DJ, Garcia-Romeu A, Johnson MW

Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.

Garcia-Romeu A, Barrett FS, Carbonaro TM +2

Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color.

Davis AK, Xin Y, Sepeda ND +2

Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy.

Strickland JC, Garcia-Romeu A, Johnson MW

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.

Garcia-Romeu A, Davis AK, Erowid E +3

Europe PMC2019

Cessation and reduction in alcohol consumption and misuse after psychedelic use.

Garcia-Romeu A, Davis AK, Erowid F +3

Europe PMC2019

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.

Garcia-Romeu A, Richards WA

Europe PMC2018

An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.

Johnson MW, Garcia-Romeu A, Johnson PS +1

Europe PMC2017

Clinical applications of hallucinogens: A review.

Garcia-Romeu A, Kersgaard B, Addy PH

Europe PMC2016